The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study
Retrospective 157 inpatients and 185 outpatients in Egypt, showing improved recovery with mebendazole. For outpatients, the trreatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable.
risk of hospitalization, 51.6% lower, RR 0.48, p = 0.33, treatment 3 of 94 (3.2%), control 6 of 91 (6.6%), NNT 29.
|
recovery time, 42.9% lower, relative time 0.57, p < 0.001, treatment 94, control 91.
|
risk of death, 50.9% lower, RR 0.49, p = 0.35, treatment 3 of 68 (4.4%), control 8 of 89 (9.0%), NNT 22, late treatment result.
|
risk of mechanical ventilation, 62.6% lower, RR 0.37, p = 0.30, treatment 2 of 68 (2.9%), control 7 of 89 (7.9%), NNT 20, late treatment result.
|
hospitalization time, 30.0% lower, relative time 0.70, p < 0.001, treatment 68, control 89, late treatment result.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Galal et al., 10 Dec 2022, retrospective, Egypt, peer-reviewed, 11 authors, study period 1 June, 2020 - 30 August, 2020.
Contact:
zgobaramd@gmail.com.
Abstract: Hindawi
Advances in Virology
Volume 2022, Article ID 3014686, 6 pages
https://doi.org/10.1155/2022/3014686
Research Article
The Use of Mebendazole in COVID-19 Patients: An Observational
Retrospective Single Center Study
Mostafa W. Galal,1 Mahmoud Ahmed,2 Yanqiu Shao,3,4 Chao Xing,4,5 Wael Ali,6
Abd Elhamid Baly,7 Abdallah Elfky,8 Khaled Amer,9 John Schoggins,10
Hesham A. Sadek ,11,2 and Zeinab N. Gobara 7
1
School of Medicine, Aim Shams University, Cairo, Egypt
Department of Internal Medicine Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
3
Department of Statistical Science, Southern Methodist University, Dallas, TX 75275, USA
4
Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
5
McDermott Center for Human Growth and Development and Department of Bioinformatics,
University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
6
Egyptian Center for Research in Regenerative Medicine, Cairo, Egypt
7
Department of Clinical Pathology, Cura El-Nasr Hospitals, Cairo, Egypt
8
Department of Radiology, Cura El-Nasr Hospitals, Helwan university, Cairo, Egypt
9
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
10
Epartments Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
11
Departments Biophysics and Molecular Biology and Center for Regenerative Science and Medicine,
University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2
Correspondence should be addressed to Zeinab N. Gobara; zgobaramd@gmail.com
Received 5 February 2022; Revised 16 May 2022; Accepted 26 August 2022; Published 10 December 2022
Academic Editor: Shih-Chao Lin
Copyright © 2022 Mostafa W. Galal et al. Tis is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. An in-silico screen identifed mebendazole with potential antiviral activity that could be a repurposed drug against SARSCoV-2. Mebendazole is a well-tolerated and cheap antihelminthic agent that is readily available worldwide and thus could be a
therapeutic tool in the fght against COVID-19. Methods. Tis is an observational retrospective study of PCR-confrmed COVID-19
patients who received mebendazole with the intention-to-treat. Te study included an inpatient cohort (157 inpatients) and an outpatient
cohort (185 outpatients). Of the 157 inpatients and 185 outpatients, 68 (43.3%) and 94 (50.8%) received mebendazole, respectively.
Patients who presented within the same timeframe but did not receive mebendazole were used as controls. Patients received standard-ofcare treatment including remdesivir, dexamethasone, and anticoagulants as deemed necessary by the treating physician. Te following
clinical outcomes were evaluated: for the inpatient cohort, length of stay (LOS) at the hospital, need for ventilation (combined invasive
and noninvasive), and mortality; for the outpatient cohort, time to symptom resolution, need for hospitalization, and mortality. Results.
For the inpatient cohort, the median age did not difer between the treatment and control groups; 62 (56, 67) vs. 62 (56, 68), P, and there
was a comparable proportion of males in both groups; 43 (63%) vs. 55 (62%), P � 0.85. Te hospital LOS was 3.5 days shorter in the
treatment group compared to the..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit